FDA-approved pancreatic cancer drug Rasonque faces access barriers for patients

The FDA approved Rasonque, a new pancreatic cancer drug, but patient access is hindered by distribution or reimbursement issues. The approval is confirmed, but the extent and causes of access barriers are unclear. This matters because delayed access could limit real-world impact of a breakthrough therapy.